| Identification | Back Directory | [Name]
N-[trans-4-[[5′-Chloro-6-[[(3-fluorophenyl)methyl]amino][2,4′-bipyridin]-2′-yl]amino]cyclohexyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]benzamide | [CAS]
2700286-66-2 | [Synonyms]
| [Molecular Formula]
C36H39ClFN7O2 | [MOL File]
2700286-66-2.mol | [Molecular Weight]
656.19 |
| Chemical Properties | Back Directory | [Boiling point ]
864.6±65.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
12.98±0.70(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity[1]. | [References]
[1] Kuang Z, et al. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma. Br J Cancer. 2023 Oct 26. DOI:10.1038/s41416-023-02464-y |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|